NO20062691L - Azabicykliske heterocykler som cannabinoide reseptormodulatorer - Google Patents
Azabicykliske heterocykler som cannabinoide reseptormodulatorerInfo
- Publication number
- NO20062691L NO20062691L NO20062691A NO20062691A NO20062691L NO 20062691 L NO20062691 L NO 20062691L NO 20062691 A NO20062691 A NO 20062691A NO 20062691 A NO20062691 A NO 20062691A NO 20062691 L NO20062691 L NO 20062691L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- receptor modulators
- cannabinoid receptor
- compounds
- azabicyclic
- Prior art date
Links
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Foreliggende søknad beskriver forbindelser med formel I, farmasøytiske preparater som omfatter minst en forbindelse med formel I og eventuelt ett eller flere ytterligere terapeutiske midler, og metoder for behandling ved anvendelse av forbindelsene i henhold til Formel I, både alene og i kombinasjon med ett eller flere ytterligere terapeutiske midler.Forbindelsene har den generelle formel I,. inkludert alle prodrugs, farmasøytisk akseptable salter og stereoisomerer, R,,,,5, m og n er beskrevet her.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53145103P | 2003-12-19 | 2003-12-19 | |
US11/016,198 US7816357B2 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
PCT/US2004/042878 WO2005063762A1 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062691L true NO20062691L (no) | 2006-09-14 |
Family
ID=34742367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062691A NO20062691L (no) | 2003-12-19 | 2006-06-12 | Azabicykliske heterocykler som cannabinoide reseptormodulatorer |
Country Status (21)
Country | Link |
---|---|
US (1) | US7816357B2 (no) |
EP (1) | EP1697371B1 (no) |
JP (1) | JP2007514770A (no) |
KR (1) | KR20060103265A (no) |
AT (1) | ATE360631T1 (no) |
AU (1) | AU2004309368A1 (no) |
BR (1) | BRPI0417820A (no) |
CA (1) | CA2550375A1 (no) |
CY (1) | CY1106679T1 (no) |
DE (1) | DE602004006166T2 (no) |
DK (1) | DK1697371T3 (no) |
ES (1) | ES2284081T3 (no) |
HK (1) | HK1095138A1 (no) |
HR (1) | HRP20070267T3 (no) |
IL (1) | IL176110A0 (no) |
IS (1) | IS8503A (no) |
NO (1) | NO20062691L (no) |
PL (1) | PL1697371T3 (no) |
PT (1) | PT1697371E (no) |
RU (1) | RU2006126123A (no) |
WO (1) | WO2005063762A1 (no) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1697371B1 (en) | 2003-12-19 | 2007-04-25 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
CA2581596A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
EP1814590B2 (en) * | 2004-11-01 | 2013-12-11 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
DK1958948T3 (da) | 2005-12-07 | 2011-10-31 | Sumitomo Chemical Co | Pyridazinforbindelse og anvendelse deraf |
US8258136B2 (en) | 2005-12-07 | 2012-09-04 | Sumitomo Chemical Company, Limited | Pyridazine compound and use thereof |
WO2007096489A1 (fr) * | 2006-02-17 | 2007-08-30 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
EP1986638A2 (en) * | 2006-02-21 | 2008-11-05 | Ampla Pharmaceuticals Inc. | Cb1 antagonists and inverse agonists |
EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
US20080140450A1 (en) * | 2006-11-28 | 2008-06-12 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with norfluoxetine |
CN101631789A (zh) | 2006-12-14 | 2010-01-20 | 百时美施贵宝公司 | 作为大麻素受体调节剂的氮杂双环杂环 |
FR2910001B1 (fr) | 2006-12-18 | 2009-03-20 | Sod Conseils Rech Applic | Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament |
AR064962A1 (es) * | 2007-01-22 | 2009-05-06 | Syngenta Participations Ag | Derivados de piridazina utiles como fungicidas |
JP2008222603A (ja) * | 2007-03-09 | 2008-09-25 | Institute Of Physical & Chemical Research | 神経変性疾患の予防・治療剤 |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
DE102008000872A1 (de) | 2007-04-11 | 2008-11-13 | Basf Se | Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel |
US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
MX356965B (es) | 2007-04-11 | 2018-06-21 | Omeros Corp | Composiciones y metodos para profilaxis y tratamiento de adicciones. |
EP2170350B1 (en) * | 2007-06-21 | 2013-09-11 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
US20090036426A1 (en) * | 2007-07-30 | 2009-02-05 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP2011503180A (ja) * | 2007-11-14 | 2011-01-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 肥満ならびに肥満関連の疾患および障害の処置方法 |
WO2010079241A1 (es) * | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012030165A2 (ko) | 2010-08-31 | 2012-03-08 | 서울대학교산학협력단 | P P A R δ 활성물질의 태자재프로그래밍용도 |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012142388A2 (en) * | 2011-04-15 | 2012-10-18 | New York University | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders |
JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
RS57640B1 (sr) | 2013-03-27 | 2018-11-30 | Hoffmann La Roche | Genetski markeri za predviđanje odgovora na terapiju |
PE20161393A1 (es) * | 2014-01-29 | 2017-01-08 | Neuropore Therapies Inc | Heteroaril amidas como inhibidores de agregacion de proteina |
CA2953483C (en) | 2014-07-30 | 2023-04-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994898A (en) * | 1975-10-16 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones |
IT1164198B (it) | 1983-04-28 | 1987-04-08 | Isf Spa | Preparazione di un derivato piridazinico farmacologicamente attivo |
JPS61106576A (ja) | 1984-10-31 | 1986-05-24 | Nippon Soda Co Ltd | トリアゾロピリダジン−3−オン誘導体及び製造方法 |
AU723098B2 (en) | 1996-07-25 | 2000-08-17 | Merck Sharp & Dohme Limited | Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
WO2000020417A1 (fr) | 1998-10-06 | 2000-04-13 | Takeda Chemical Industries, Ltd. | Composes de pyridazine condenses, leur procede de preparation et leur utilisation |
JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
GB0107751D0 (en) * | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
AU2003205926A1 (en) * | 2002-02-07 | 2003-09-02 | Pfizer Limited | Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome |
ATE373660T1 (de) * | 2002-03-25 | 2007-10-15 | Merck & Co Inc | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes |
CA2508731A1 (en) | 2003-02-19 | 2004-09-02 | Neurogen Corporation | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
EP1697371B1 (en) | 2003-12-19 | 2007-04-25 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
TW200530246A (en) | 2003-12-19 | 2005-09-16 | Bristol Myers Squibb Co | Azabicyclic heterocycles as cannabinoid receptor modulators |
-
2004
- 2004-12-17 EP EP04815007A patent/EP1697371B1/en active Active
- 2004-12-17 AU AU2004309368A patent/AU2004309368A1/en not_active Abandoned
- 2004-12-17 BR BRPI0417820-3A patent/BRPI0417820A/pt not_active IP Right Cessation
- 2004-12-17 DE DE602004006166T patent/DE602004006166T2/de not_active Expired - Fee Related
- 2004-12-17 KR KR1020067011999A patent/KR20060103265A/ko not_active Application Discontinuation
- 2004-12-17 ES ES04815007T patent/ES2284081T3/es active Active
- 2004-12-17 JP JP2006545567A patent/JP2007514770A/ja active Pending
- 2004-12-17 DK DK04815007T patent/DK1697371T3/da active
- 2004-12-17 PL PL04815007T patent/PL1697371T3/pl unknown
- 2004-12-17 AT AT04815007T patent/ATE360631T1/de not_active IP Right Cessation
- 2004-12-17 CA CA002550375A patent/CA2550375A1/en not_active Abandoned
- 2004-12-17 US US11/016,198 patent/US7816357B2/en active Active
- 2004-12-17 WO PCT/US2004/042878 patent/WO2005063762A1/en active Application Filing
- 2004-12-17 PT PT04815007T patent/PT1697371E/pt unknown
- 2004-12-17 RU RU2006126123/04A patent/RU2006126123A/ru not_active Application Discontinuation
-
2006
- 2006-06-04 IL IL176110A patent/IL176110A0/en unknown
- 2006-06-08 IS IS8503A patent/IS8503A/xx unknown
- 2006-06-12 NO NO20062691A patent/NO20062691L/no not_active Application Discontinuation
-
2007
- 2007-02-16 HK HK07101918A patent/HK1095138A1/xx not_active IP Right Cessation
- 2007-06-08 HR HR20070267T patent/HRP20070267T3/xx unknown
- 2007-06-26 CY CY20071100845T patent/CY1106679T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
IL176110A0 (en) | 2006-10-05 |
DE602004006166D1 (de) | 2007-06-06 |
HRP20070267T3 (en) | 2007-08-31 |
DE602004006166T2 (de) | 2008-01-10 |
CA2550375A1 (en) | 2005-07-14 |
ES2284081T3 (es) | 2007-11-01 |
KR20060103265A (ko) | 2006-09-28 |
IS8503A (is) | 2006-06-08 |
BRPI0417820A (pt) | 2007-03-27 |
CY1106679T1 (el) | 2012-05-23 |
WO2005063762A1 (en) | 2005-07-14 |
RU2006126123A (ru) | 2008-01-27 |
US20050171110A1 (en) | 2005-08-04 |
PL1697371T3 (pl) | 2007-09-28 |
JP2007514770A (ja) | 2007-06-07 |
EP1697371B1 (en) | 2007-04-25 |
US7816357B2 (en) | 2010-10-19 |
ATE360631T1 (de) | 2007-05-15 |
DK1697371T3 (da) | 2007-09-17 |
HK1095138A1 (en) | 2007-04-27 |
PT1697371E (pt) | 2007-08-03 |
AU2004309368A1 (en) | 2005-07-14 |
EP1697371A1 (en) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062691L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
NO20062689L (no) | Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer | |
NO20062704L (no) | Azabicykliske heterocykler som cannabinoide reseptormodulatorer | |
NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
BRPI0408784A (pt) | método para usar um composto | |
NO20065904L (no) | Terapeutiske forbindelser | |
NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
WO2005037199A3 (en) | Pyrazole derivatives as cannabinoid receptor modulators | |
NO20045103L (no) | Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse | |
NO20064010L (no) | Indazolderivater og farmasoytiske preparater inneholdelse slike | |
WO2005063745A3 (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
NO20081844L (no) | Terapeutiske forbindelser | |
NO20055098L (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
NO20052182L (no) | Nye forbindelser | |
NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
NO20072089L (no) | Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav | |
NO20082214L (no) | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer | |
NO20083790L (no) | Nye terapeutiske kombinasjoner for behandling eller forebygging av psykotiske lidelser | |
NO20062307L (no) | Spirofuropyridinarylderivater | |
DE602005005967D1 (de) | Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament | |
NO20055254L (no) | Farmasoytisk kombinasjon for behandling av spastisitet og/eller smerte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |